PTCT PTC Therapeutics, Inc.

42.742.37 (+5.87%)
Close: June 18, 2019

Quote

Previous Close
$42.74
Day Range
$40.80-$43.20
52 Week Range
$27.53-$52.95
Volume
607,542
Avg Volume
953,895
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$2.50B
Enterprise Value (EV)
$2.28B
PE Ratio
-
EV/EBITDA
-33.32
Price/Sales
8.91
Price/Book
7.12
PEG Ratio
-

Financials

Revenue
$264.73M
Gross Profit
$229.19M
EBITDA
-$68.56M
EPS, ttm
-$3.52
Profit Margin
-
Revenue/Employee
$512.06K
Next Earnings Date
8/5/2019 (47 days)
Debt to Equity
44%
Debt
$14.53M
Cash
$227.59M
Net Debt
-

Performance

Beta
1.63
200 Day Moving Avg
$37.07
50 Day Moving Avg
$38.98
52 Week Change
-15.69%
YTD Change
25.98%
1 Month Change
7.97%
3 Month Change
9.29%
6 Month Change
23.46%
1 Year Change
-15.68%
2 Year Change
239.67%
5 Year Change
108.24%

Share Count

Shares Outstanding
58.4M
Float
56.6M
Restricted Shares
1.8M
Restricted Shares, %
3.08%

PTC Therapeutics, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Stuart W. Peltz

Website: http://www.ptcbio.com

Description: PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Employees: 517